Post by Mirum Pharmaceuticals, Inc.

At ENDO 2026, #TeamMirum will join the endocrinology community for four days of science, connection, and discovery — including a late-breaking rapid-fire presentation on Sunday. The presentation will feature results from the pivotal Phase 2 PROGRESS study evaluating an investigational ALK2 inhibitor in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Let us know in the comments if you’ll be there, and visit us at Booth 3834. #ENDO2026 #FOP #RareDisease